Institute Of Cancer Research, United Kingdom

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this …

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then trea…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can lower the chance of breast cancer returning in postmenopausal women with a high-risk type. About 123 participants will receive either hormone therapy alone or with abemaciclib for up to 2…

This study looks at blood samples from 25 cancer patients receiving radiation therapy. Researchers want to find specific genes that show how each person's body responds to radiation. The goal is to better understand individual reactions and possibly personalize radiation treatmen…

This study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …

This study looks at whether a simple genetic test can identify men who are more likely to have prostate cancer, so screening can be focused on them. About 300 Caucasian men aged 55 to 69 will provide a DNA sample and, if their genetic risk score is high, they will be offered a pr…

The IMPACT study is an international effort to screen men aged 40-69 who carry BRCA1, BRCA2, or mismatch repair gene mutations, which raise their risk of prostate cancer. Participants receive annual PSA tests and optional biopsies if levels are high. The goal is to learn how ofte…